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a b s t r a c t
Little is known about the tissue tropism of KI polyomavirus (KIPyV), and there are no studies to date
describing any speciﬁc cell types it infects. The limited knowledge of KIPyV tropism has hindered study of
this virus and understanding of its potential pathogenesis in humans. We describe tissues from two
immunocompromised patients that stained positive for KIPyV antigen using a newly developed immuno-
histochemical assay targeting the KIPyV VP1 (KVP1) capsid protein. In the ﬁrst patient, a pediatric bone
marrow transplant recipient, KVP1 was detected in lung tissue. Double immunohistochemical staining
demonstrated that approximately 50% of the KVP1-positive cells were CD68-positive cells of the macro-
phage/monocyte lineage. In the second case, an HIV-positive patient, KVP1 was detected in spleen and lung
tissues. These results provide the ﬁrst identiﬁcation of a speciﬁc cell type inwhich KVP1 can be detected and
expand our understanding of basic properties and in vivo tropism of KIPyV.
& 2014 Elsevier Inc. All rights reserved.
Introduction
KI polyomavirus (KIPyV) was discovered in 2007 in patients
with respiratory tract infections (Allander et al., 2007). Subsequent
studies have detected KIPyV in respiratory tract secretions, blood,
stool and tonsil tissue (Babakir-Mina et al., 2011) and have
suggested a seroprevalence of 55–70% (Nguyen et al., 2009; Kean
et al., 2009), with infection occurring most frequently in child-
hood. KIPyV is not currently associated with any human disease(s).
However, other polyomaviruses are known to be important human
pathogens. BK polyomavirus (BKPyV) causes BK nephropathy and
hemorrhagic cystitis, while JC polyomavirus (JCPyV) is the etiolo-
gical agent of progressive multifocal leukoencephalopathy. For
both BKPyV and JCPyV, disease only manifests when the host is
immunocompromised (Knowles, 2006). As the more recently
discovered Merkel cell carcinoma polyomavirus and Trichodyspla-
sia spinulosa-associated polyomavirus are also thought to cause
disease in the context of immunosuppression (Kazem et al., 2012;
Gjoerup and Chang, 2010), a signiﬁcant question is whether KIPyV
follows this paradigm and causes disease in immunocompromised
patients.
Since little is known about the in vivo tropism of KIPyV, it is not
yet possible to accurately identify potential diseases with which it
may be associated. The virus has most commonly been detected in
respiratory secretions, but there have been only minimal efforts to
explore additional specimen types. In addition, prior studies have
relied exclusively on PCR approaches to detect viral genomes in
bulk-extracted nucleic acid, making it impossible to deﬁne the
speciﬁc cell type(s) that harbor KIPyV. There have also been no
published reports describing the detection of KIPyV antigens in
tissues. In order to deﬁne the tissue and cell tropism of KIPyV and
as a step toward understanding the role of KIPyV in human
disease, we developed an immunohistochemical (IHC) assay tar-
geting KIPyV VP1 (KVP1), the viral capsid protein. We applied this
assay to tissue specimens from patients positive for KIPyV by PCR
described in the published literature (Siebrasse et al., 2012; Sharp
et al., 2009). Tissues from two different patients were positive.
KVP1 was detected in the lung tissue of a pediatric bone marrow
transplant recipient, and a portion of the positive cells was
identiﬁed as being CD68-positive using a double immunohisto-
chemical stain. In addition, KVP1 was detected in the spleen and
lung tissues of a deceased HIV-positive patient. These results
provide the ﬁrst insights into a speciﬁc cell type in which KIPyV
can be detected.
Results
Establishment of a KVP1-speciﬁc immunohistochemistry assay
To study the cell and tissue tropism of KIPyV, we established
an IHC assay using a newly developed monoclonal anti-KVP1
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antibody. To validate the new IHC assay and evaluate its speciﬁcity,
we developed a positive control cell pellet. Fig. 1a shows 293T cells
transfected with the pDEST26-KVP1 construct, which expressed
KVP1 from a CMV promoter, and stained with the KVP1 antibody.
Several cells showed prominent dark brown staining (Fig. 1a and
b), while cells from both a sequentially cut slide stained with the
isotype control (Fig. 1c) and mock transfected 293T cells stained
with the KVP1 antibody (Fig. 1d) did not.
To independently evaluate the speciﬁcity of the KVP1 mono-
clonal antibody, a subset of the transfected cells were lysed to
extract proteins for Western blot analysis (Fig. 1e). As negative
controls, lysates of 293T cells from a mock transfection and from a
transfection of an analogous plasmid expressing the VP1 protein of
WU polyomavirus (pDEST26-WVP1) were included. We ﬁrst
blotted with a primary antibody against WU polyomavirus VP1
(WVP1), which is the most closely related virus to KIPyV and has
also been detected in respiratory tract secretions. A single band
was detected in the WVP1 lysate, while no band was seen in the
KVP1 lysate or in the mock transfected cells (Fig. 1e). After the
membrane was stripped, we blotted with the KVP1 monoclonal
antibody. A single band corresponding to the predicted size of
KVP1 was detected in the KVP1 lysate, while no band is seen in
mock transfected cells or in the WVP1 lysate (Fig. 1e). The blot was
stripped a second time and blotted for actin (Millipore #MAB1501,
Billerica, MA) as a loading control. Given these data, we concluded
the KVP1 antibody is speciﬁc for KI polyomavirus, and the KVP1
IHC assay can detect KI polyomavirus antigen in formalin-ﬁxed
parafﬁn-embedded cell pellets. Potential cross reactivity of the
KVP1 assay with human polyomaviruses 6 and 7, which are the
next most closely related polyomaviruses to KIPyV, was not
explicitly tested. However, we believe cross reactivity with these
viruses to be highly unlikely as they are much more divergent
from KIPyV than WUPyV.
Detection of KVP1 in a pediatric transplant recipient
During the course of a recent study to evaluate the prevalence
of human polyomaviruses in a prospective pediatric transplant
cohort (Siebrasse et al., 2012), we identiﬁed one patient (#3001)
whose nasopharyngeal aspirate sample (NPA) was strongly posi-
tive for KIPyV by real-time PCR. The patient's clinical parameters
have been described in detail (Siebrasse et al., 2012). In brief, the
patient was a 17-month-old child who received a bone marrow
transplant as treatment for Fanconi anemia in April 2009. The
patient's disease course was complicated by recurrent pulmonary
hemorrhage, severe graft-versus-host disease (GVHD), and renal
failure. The patient ultimately died of acute respiratory failure and
extensive pulmonary hemorrhage several months later. The
autopsy of the lung revealed evidence of chronic pulmonary
hemorrhage with numerous hemosiderin-laden macrophages in
the alveolar spaces. Diffuse alveolar hemorrhage leading to
respiratory failure was the listed likely cause of death. Infection
was considered less likely due to the negative results of routine
microbiology testing (via culture and/or PCR). There was no
signiﬁcant inﬂammation or airway ﬁbrosis to suggest GVHD in
the lungs. A NPA sample collected 24 days prior to the death of the
patient was strongly positive for KIPyV (1.3109 genome copies
per mL of transport media) (Siebrasse et al., 2012).
Tissue blocks obtained at autopsy from 17 different body sites
were available for KVP1 IHC testing. These included skin, liver,
lung, esophagus, stomach, small intestine, large intestine, pan-
creas, spleen, right kidney, left kidney, bladder, left ventricle, right
ventricle and pituitary, right adrenal and left adrenal glands. Of
these, only the lung was positive by IHC (Fig. 2). Two patterns of
cellular staining were seen—strong, dark nuclear staining (arrows)
and weaker, granular staining exclusively in the cytoplasm (arrow
heads). Several controls were performed on serial sections to
Fig. 1. Validation of anti-KVP1 monoclonal antibody speciﬁcity. Immunohistochemistry (IHC) of 293T cells transfected with pDEST26-KVP1 and stained with (A, B) a KVP1
monoclonal antibody or with (C) an isotype control. (D) IHC of mock transfected 293T cells stained with a KVP1 monoclonal antibody. Panels A and C are at 400 ; panel B is
at 600 , and panel D is at 200 . (E) Western blot using a WVP1 monoclonal antibody of protein lysates from mock transfected 293T cells (lane 3) or cells transfected with
pDEST26-KVP1 (lane 2) or pDEST26-WVP1 (lane 1). The blot was stripped and re-blotted using a KVP1 monoclonal antibody.
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analyze this staining pattern, including a corresponding IgG2b
isotype control (Fig. 2a) and staining performed without the primary
antibody or without both the primary and secondary antibodies (not
shown). The weaker cytoplasmic staining was occasionally seen in
controls and thus was potentially non-speciﬁc, but the strong nuclear
staining was exclusively seen in the KVP1 stained tissue. Our
subsequent analyses focused on these strong, nuclear staining cells.
There were positive cells scattered throughout the section (similar to
Fig. 2b and c) with a few localized regions containing a high density
of positive staining cells.
Detection of KVP1 in CD68-positive cells
We used a double IHC (dIHC) staining approach to identify the
cell type(s) that were KVP1-positive. Many of the positive cells were
found within the alveolar spaces and were morphologically consis-
tent with immune cells, so we began our analysis by establishing a
dIHC assay using the KVP1 monoclonal antibody and an antibody
against human CD45, which marks all cells of hematopoietic origin.
Double IHC using the CD45/KVP1 assay showed clearly staining
double positive cells throughout the tissue (Fig. 3b, c, and e). Of the
105 KVP1-positive cells counted in one tissue section, 51 (49%) were
also CD45-positive. An isotype control (IgG2b for the KVP1 antibody)
performed on a serial section (Fig. 3a and d) was negative. A
hematoxylin and eosin stain showed dark staining “grape-like”
clusters, morphologically consistent with phagocytic cells (Fig. 3f).
Based on these data, we hypothesized that the CD45/KVP1-positive
cells may be alveolar macrophages
To test this hypothesis, we established a second dIHC assay
using the KVP1 monoclonal antibody and an antibody against
human CD68, which primarily marks macrophages and mono-
cytes, and applied it to the lung tissue from patient 3001. Clear
double staining was seen in 48% of KVP1-positive cells (Fig. 4a–
c), while no staining was seen in the isotype control (not shown).
This demonstrated a subset of the KVP1-positive cells were likely
to be alveolar macrophages. In addition, the morphology of a
positive staining cell presented in Fig. 4c resembles that of a foamy
macrophage, a speciﬁc morphotype of macrophage loaded with
lipid droplets (Russell et al., 2009).
We next attempted to identify the remaining subset of KVP1-
positive cells that were CD45-negative. Based on the observation
that KVP1-positive cells lined the alveoli in another case described
below, we established a dIHC assay using antibodies against KVP1
and cytokeratin, which labels epithelial cells. While cells staining
single positive for either KVP1 or cytokeratin were evident, no
double positive cells were seen (Supplementary Fig. 1), suggesting
KIPyV was not present in epithelial cells in this lung specimen.
One caveat to this interpretation is the absence of a gold standard
positive control (i.e. epithelial cells known to express KVP1 in lung
tissue) to validate the cytokeratin/KVP1 double stain in the context
of lung tissue.
Detection of KVP1 in an HIV-positive patient
Sharp et al. (2009) previously screened 97 autopsy samples of
lymphoid tissue by PCR and identiﬁed four samples positive for KIPyV,
three from AIDS patients and one from an HIV-negative patient. A
spleen sample from one patient had KVP1-positive staining cells
scattered throughout the section with a few localized regions contain-
ing a high density of positive staining cells (Fig. 5a–c). This sample was
derived from a 42-year-old HIV-positive male who had initially
presented with peripheral neuropathy and atypical mycobacterial
infection. He was re-admitted four months later for cytomegalovirus
(CMV) retinitis, and his condition continued to deteriorate until death.
Autopsy showed disseminated mycobacterial infection, CMV esopha-
gitis, low grade CMV encephalitis and vacuolar myelopathy.
Most of the KVP1 positive cells were in areas of white pulp,
which also showed poorly formed granulomas attributed to a
mycobacterial infection, according to the autopsy report. One such
example with positive cells surrounding a blood vessel consistent
with splenic white pulp is shown in Fig. 5b and c. The isotype
matched control antibody (J6.36) targeting the E2 glycoprotein of
Hepatitis C virus (Sabo et al., 2011) yielded no staining, consistent
with speciﬁc anti-KVP1 staining (Fig. 5a). Based on morphology
and the detection of KVP1 in CD68-positive cells in the previously
described case, we suspected hematopoietic cells may harbor
KIPyV. Double staining of KVP1 with CD45 or CD68, however,
yielded only single positive cells (Supplementary Fig. 2). Given
these negative results, we hypothesized that the KVP1-positive
cells may be endothelial cells, so we established a dIHC assay with
the anti-KVP1 antibody and an antibody against CD31, which
primarily marks endothelial cells. However, only single positive
cells were seen (Supplementary Fig. 3). Therefore, the identity of
the positive staining cells in the spleen is currently unknown.
We obtained sections of all other available tissues from this
patient from the tissue bank for further analysis. These included
the adrenal gland, carotid artery, colon, heart, ileum, kidney, liver,
lung, pancreas, pituitary gland, prostate, testis, thyroid gland, tongue
and a lymph node. Besides the spleen, only the lung specimen was
positive by IHC for KVP1 with strong staining throughout the tissue
as presented in Fig. 5d–f. Closer inspection of the lung showed KVP1
staining of some alveolar surfaces, raising the possibility that the
infected cells might be pneumocytes. In addition, other cells (Fig. 5f,
arrows) of unknown identity that did not border the alveolar spaces
Fig. 2. Immunohistochemical staining of human lung with a KVP1 monoclonal antibody. Tissue stained with (A) an isotype control or (B) the KVP1 antibody (both at 200 ).
(C) Higher magniﬁcation (600 ) of KVP1 staining in panel B.
E.A. Siebrasse et al. / Virology 468-470 (2014) 178–184180
were also positive, suggesting that KIPyV infects multiple cell types
present in the lung. Deﬁnitive identiﬁcation of the speciﬁc cell types
staining positive in this tissue was not possible due to the lack of
available tissue. According to the autopsy report, the lungs showed
bronchopneumonia, but no granulomas or acid fast bacilli were
identiﬁed. The lung weights and pathological ﬁndings did not
suggest an acute interstitial pneumonia.
Discussion
We detected KIPyV VP1 (KVP1) antigen in lung and splenic
tissues for the ﬁrst time using a newly developed IHC assay. In one
patient, we identiﬁed a subset of the KVP1-positive lung cells as
being CD68-positive. Together with morphologic data, these
results suggest that alveolar macrophages harbor KVP1. The
majority of prior KIPyV studies focused on respiratory secretions
and relied on PCR of bulk-extracted DNA, making it impossible to
determine speciﬁc cell types. Nonetheless, the simplest hypoth-
eses regarding KIPyV tropism have focused on respiratory epithe-
lial cells, the cell types infected by common respiratory viruses
such as RSV (Hacking and Hull, 2002) and inﬂuenza (Kuiken and
Taubenberger, 2008). While the IHC results alone do not prove that
KIPyV can productively infect the CD68-positive cells, they do
demonstrate expression of capsid protein from the late region of
the genome, a step in the polyomavirus life cycle that is generally
Fig. 3. Detection of KIPyV VP1 in cells of hematopoietic origin in the lung. Lung tissue stained with a double IHC assay using antibodies against (A, D) CD45 (brown) and
IgG2b (blue) as an isotype control or (B, C, E) CD45 (brown) and KVP1 (blue). (F) Hematoxylin and eosin-stained lung tissue. Panels A and B are at 400 ; panel C is at
1000 ; panels D and E are at 600 , and panel F is at 200 .
Fig. 4. KIPyV VP1 detection in CD68-positive cells. Double IHC staining with antibodies against CD68 (brown) and KVP1 (blue) at (A) 400 and (B) 1000 . (C) A second
double positive cell from another ﬁeld of the tissue at 1000 .
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thought to occur concomitantly with DNA replication (White et al.,
2009). These results also suggest that efforts to develop in vitro
culture systems for KIPyV should explore the possibility that
macrophage and monocyte cell lines may be permissive for
productive infection.
Alveolar macrophages are long-lived, terminally-differentiated
cells that permanently reside in the lung. They are thought to be
one of the ﬁrst cell types to respond to pathogens (Schneberger et
al., 2011). The identiﬁcation of alveolar macrophages as a potential
site of KIPyV infection greatly expands our understanding of KIPyV
tropism and provides new insights into the biology of KIPyV. The
infection of macrophages and monocytes by BK polyomavirus
(Traavik et al., 1988), early hematopoietic progenitor cells by JC
polyomavirus (Monaco et al., 1996) and detection of Merkel cell
polyomavirus (Mertz et al., 2010) in monocytes have been
reported. Alveolar macrophages display α-2,3- and α-2,6-linked
sialic acid (Yu et al., 2011), both are known receptors for other
polyomaviruses. BK polyomavirus and murine polyomavirus both
bind to α-2,3-linked sialic acid, and JC polyomavirus binds to
α-2,6-linked sialic acid (Neu et al., 2009). It is currently unknown
what receptors are utilized by KIPyV, but it is possible that KIPyV
might use similar receptors to BK and JC polyomaviruses.
The detection of KVP1 in CD68-positive cells could arise from
one or more possible scenarios. First, alveolar macrophages may
be susceptible to productive infection. Alternatively, it is also
conceivable that circulating monocytes become infected in the
bloodstream and remained infected after differentiation into
alveolar macrophages in the lung. Third, other respiratory viruses,
such as type A inﬂuenza virus, are known to abortively infect
alveolar macrophages (Short et al., 2012), where infection and
subsequent steps of the viral life cycle occur but no virions are
produced. Finally, we cannot rule out the formal possibility that
the presence of KVP1 merely reﬂects phagocytosis of other virus
infected cells. However, given the observation that KVP1 staining
is nuclear, this seems like an unlikely option. Bona ﬁde infection
versus abortive infection of macrophages by KIPyV would likely
lead to different outcomes, as is seen during inﬂuenza A infection
(Short et al., 2012). For example, an abortive infection would make
the macrophage a dead end host and might allow the human host
to mount a more effective immune response and delay viral
spread. Conversely, a productive infection, whether initiated in
the blood or lung, could incite a pro-inﬂammatory response from
the infected macrophages, leading to greater immunopathology
and increased viral spread.
In both of the cases presented here, the patients were immu-
nocompromised and had lung tissues with detectable KVP1,
supporting the hypothesis that the lung is an important site for
KIPyV infection. However, the two cases presented with unique
clinical features and disease pathologies. Patient #3001 was a
pediatric patient who underwent a bone marrow transplant with
multiple complications, including severe graft-versus-host disease,
and died from acute respiratory failure and extensive pulmonary
hemorrhage. In contrast, the other patient was an HIV-positive
adult with multiple AIDS-deﬁning illnesses at the time of death.
The detection of KVP1 in the spleen of the adult HIV case and its
absence in patient 3001 may reﬂect a distinct modality of KIPyV
infection or possibly a dependence on HIV-mediated immunosup-
pression. Regardless, the IHC detection of KVP1 in the spleen of
this patient corroborates the published PCR results (Sharp et al.,
2009), and provides evidence that additional speciﬁc cell types
harbor KIPyV. Collectively, these results demonstrate that KVP1
can be detected in multiple distinct cell types in more than one
Fig. 5. Immunohistochemical staining of human spleen and lung with a KVP1 monoclonal antibody. Tissue surrounding a splenic blood vessel consistent with splenic white
pulp stained with (A) the isotype control or (B) the KVP1 antibody (both at 400 ). (C) Hematoxylin and eosin staining of the same splenic area at 200 . Gas exchange tissue
near a bronchiole stained with (D) the isotype control at 200 or with (E) the KVP1 antibody at 200 and (F) 600 .
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tissue type in the human body and suggest the possibility that
additional parameters, such as host immune status or age, may be
important factors affecting viral tropism. While the role of KIPyV
in human disease remains to be determined, it is interesting to
speculate about a potential role in respiratory illness given the
high titers of KIPyV in patient 3001.
In conclusion, we have established an immunohistochemical
assay to detect KIPyV antigen in human tissue. We also demon-
strated KVP1-positive staining in two lungs and one spleen from
two separate patient cases. Further analysis revealed a subset of
the positive cells in one lung was likely to be alveolar macro-
phages. This discovery furthers our understanding of KIPyV
biology. Moreover, the knowledge that KIPyV can be detected in
CD68-positive cells will beneﬁt future efforts to develop cell
culture systems for propagation of this virus.
Materials and methods
Development of anti-KVP1 monoclonal antibodies
To develop anti-KVP1 monoclonal antibodies, the KVP1 Gate-
way pENTR/SD/D-TOPO construct previously described (Nguyen et
al., 2009) was transferred into the Gateway pDEST17 plasmid (Life
Technologies, Carlsbad, CA) and expressed in Escherichia coli. The
resulting recombinant His-tagged KVP1 protein was puriﬁed via
an afﬁnity Ni-NTA column (Pierce Biotechnology, Rockford, IL).
A BALB/c mouse was immunized with three consecutive doses of
the puriﬁed antigen. Its spleen was harvested for hybridoma fusion
with the murine myeloma line P363Ag8.653 (Sigma-Aldrich, St.
Louis, MO). We screened for clones producing anti-KVP1 antibody
by ELISA and Western blot using puriﬁed GST-tagged KVP1 as the
target antigen. Positive clones were then screened by ELISA using
GST-tagged WVP1 (Nguyen et al., 2009), and those demonstrating
cross reactivity to WVP1 were excluded. Two rounds of limiting
dilutions were performed to achieve clonality. The anti-KVP1
monoclonal antibody used in the following experiments, NN-
Ab03, was isotype IgG2b. The anti-WVP1 monoclonal antibody
(NN-Ab06) used shown in Fig. 1e is developed in an analogous
manner and is also isotype IgG2b.
Generation of a KVP1 positive control
We generated a positive control for the immunohistochemistry
assay by transfecting 293T cells with a plasmid (pDEST26, Life
Technologies, Carlsbad, CA) encoding KVP1. Cells were harvested
three days after transfection, and a portion was ﬁxed in 10%
neutral buffered formalin for 24 h, embedded in parafﬁn, and
sections of the cell block were transferred to glass slides.
Immunohistochemistry (IHC)
Tissue sections were deparafﬁnized in three changes of xylene
and then rehydrated in a series of graded ethanol solutions.
Antigen retrieval was accomplished in citrate buffer pH 6.0
(10 mM citric acid, 0.05% Tween 20) at 95 1C in a water bath for
35 min. Slides were then stained using the Histostains-Plus 3rd
Generation IHC Detection kit (Life Technologies, Carlsbad, CA)
according to the manufacturer's instructions, with Superblock
T20 (Thermo #37516, Rockford, IL) used as the blocking agent.
The aforementioned KVP1 monoclonal antibody or an isotype
control (mouse IgG2b, BD Biosciences #557351, San Jose, CA)
was used as the primary antibody. After completion of the
Histostain protocol, the slides were counterstained with hematox-
ylin and dehydrated in a series of graded ethanol solutions and
xylene.
Slight modiﬁcations to this assay were used for staining
performed on the pediatric transplant recipient's tissue. Tissue
sections were deparafﬁnized in xylene for 15 min and then
rehydrated in a series of graded ethanol solutions. Endogenous
peroxidases were quenched in 3% hydrogen peroxide for 15 min.
Antigen retrieval was accomplished in citrate buffer in a pre-
warmed pressure cooker (Nesco PC6–25, Two Rivers, WI) for 3 min
on the high setting. After blocking in 1.5% normal horse serum
(Vector Labs #S-200, Burlingame, CA), the tissues were incubated
ﬁrst in primary antibody and then in secondary antibody (bioti-
nylated anti-mouse IgG, Vector BA-2000, Burlingame, CA). The
staining was developed using the Vectastain standard ABC kit
(Vector Labs #PK-6100, Burlingame, CA) and DAB (Vector Labs
#SK-4100, Burlingame, CA), counterstained with hematoxylin and
dehydrated in a series of graded ethanol solutions and xylene.
Double immunohistochemistry (dIHC)
Double staining of the tissues utilized a protocol similar to that
mentioned above for the transplant recipient's tissues with the
addition of several steps. Following chromagen development of
the ﬁrst antibody using either DAB or ImmPACT SG (Vector Labs
#SK-4705, Burlingame, CA), tissues were blocked with avidin and
biotin (Vector Labs #SP-2001, Burlingame, CA) and a second time
with 1.5% normal horse serum. They were incubated with the
second primary and secondary antibodies and then developed as
per the above IHC protocol. Other primary monoclonal antibodies
used were against CD45 (BD Biosciences #555480, San Jose, CA),
CD68 (Dako #M081401, Glostrup, Denmark) and CD31 (Dako
#M0823, Glostrup, Denmark). Citrate buffer was used for antigen
retrieval in the double IHC assays with CD45 and CD68, while Tris-
EDTA buffer pH 9.0 (10 mM Tris, 1 mM EDTA, 0.05% Tween 20) was
utilized for the CD31 double IHC assay.
Image manipulation
Images were cropped to squares. The resolution was changed to
500 dpi in Photoshop with constrained proportions and no resam-
pling. No other image manipulation was conducted.
Human studies
This study was approved by the Human Research Protection
Ofﬁce of Washington University in St. Louis under IRB 201108413.
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